文献速递肿瘤 PET/CT

HER2靶向PET/CT显像为区分HER2零表达、低表达与阳性乳腺癌提供潜在生物标志物

HER2-targeted PET/CT imaging provides potential biomarkers for differentiating HER2-zero, -low, and -positive breast cancer.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2025-05-08

这项前瞻性研究于2024年5月至2025年1月纳入57例女性初诊乳腺癌患者(58个原发灶),同期行68Ga-HER2-affibody与18F-FDG PET/CT。HER2-SUVmean是区分HER2低表达/阳性与零表达独立预测因子(P=0.01;OR=2.8),AUC为0.91。

要点

  • HER2-low与HER2-positive组中,HER2-TBR均高于FDG-TBR(P<0.001)。
  • HER2-SUVmean为区分HER2-low/positive与-zero的独立预测因子(P=0.01;OR=2.8),AUC为0.91。
  • 按详细HER2免疫组化分层,HER2-SUVmax、HER2-SUVmean与HER2-TBR存在组间差异(P<0.05)。

核心结论

  • HER2靶向PET/CT显像在表征原发灶HER2状态方面较18F-FDG PET/CT显像具有明显优势。
  • 基于HER2-affibody的参数在不同HER2状态间差异显著,可能成为筛选可从HER2靶向抗体药物偶联物(ADCs)获益的HER2低表达/阳性患者的潜在影像学指标。

研究设计与样本

  • 前瞻性研究,于2024年5月至2025年1月开展,初诊乳腺癌参与者均行68Ga-HER2-affibody与18F-FDG PET/CT检查。
  • 共纳入57例女性初诊乳腺癌参与者(58个原发灶),分析PET参数与HER2表达状态(HER2零表达、低表达、阳性)的关系。

主要发现

  • 在68Ga-HER2-affibody与18F-FDG PET/CT的配对比较中,HER2低表达组与HER2阳性组的HER2-TBR分别高于FDG-TBR(P<0.001)。
  • HER2-SUVmax与HER2-SUVmean在多数比较中表现出差异,尤其是HER2零表达与低表达之间(P<0.05)。
  • HER2-SUVmean是区分HER2低表达/阳性与零表达的独立预测因子(P=0.01;OR=2.8),AUC为0.91。
  • 按详细HER2免疫组化分层,HER2-SUVmax、HER2-SUVmean与HER2-TBR呈现组间差异(P<0.05)。

关键数值与推荐

  • HER2-SUVmean区分HER2低表达/阳性与零表达:P=0.01;OR=2.8;AUC=0.91。
  • HER2低表达组与HER2阳性组中HER2-TBR分别高于FDG-TBR(P<0.001)。
  • HER2零表达与低表达比较中HER2-SUVmax、HER2-SUVmean存在差异(P<0.05)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Human epidermal growth factor receptor 2 (HER2)-targeted antibody-drug conjugates (ADCs) in breast cancer is progressing rapidly, asking for precise categorization of HER2 expression. Our aim was to explore the HER2-affibody uptake characteristics in breast cancer and to find potential biomarkers for differentiating HER2 status, in comparison with 18F-FDG PET/CT. METHODS: In this prospective study conducted from May 2024 to Jan 2025, participants with newly diagnosed breast cancer underwent both 68Ga-HER2-affibody and 18F-FDG PET/CT examinations. The relationship between PET parameters (such as maximum standardized uptake value (SUVmax), mean standardized uptake value (SUVmean), tumor-to-background SUV ratio (TBR)) and HER2 expression statuses (HER2-zero, -low and -positive) was analyzed. RESULTS: A total of 57 female participants (58 primary lesions) with newly diagnosed breast cancer were included. In the paired comparison of 68Ga-HER2-affibody and 18F-FDG PET/CT, HER2-TBR was higher than FDG-TBR in the HER2-low and HER2-positive group, respectively (P < 0.001). HER2-SUVmax and HER2-SUVmean exhibited differences across most comparisons, especially HER2-zero vs. -low (P < 0.05). HER2-SUVmean emerged as an independent predictor (P = 0.01; OR: 2.8) for differentiating HER2-low/positive and -zero, yielding an AUC of 0.91. Under detailed HER2 immunohistochemistry, HER2-SUVmax, -SUVmean and -TBR demonstrated intergroup differences (P < 0.05). CONCLUSION: HER2-targeted PET/CT imaging demonstrated distinct advantages over 18F-FDG PET/CT imaging in characterizing the HER2 status of primary lesions. Parameters based on HER2-affibody differed significantly among different HER2 statuses, and might be potential imaging indicators for screening patients with HER2-low/positive who could benefit from HER2-targeted ADCs. GOV IDENTIFIER: NCT06289517 (2024-03-04).

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Gao Y, Yin L, Duan X, et al. HER2-targeted PET/CT imaging provides potential biomarkers for differentiating HER2-zero, -low, and -positive breast cancer. Eur J Nucl Med Mol Imaging. 2025. PMID: 40338302. doi:10.1007/s00259-025-07220-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。